Testing JSKN027 for advanced solid tumors that have progressed
Part of Cancer clinical trials.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has grown or spread despite standard treatments like chemotherapy or other approved therapies.
- You must have a tumor that can be measured on a CT or MRI scan (not including brain tumors).
- Your blood counts, liver, kidney, and heart function must be within a healthy range (checked by blood tests).
- You cannot have active brain tumors, severe lung disease, or an autoimmune condition that requires immune-suppressing medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
This trial tests a new drug called JSKN033 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if JSKN033 is safe and effective for these patients.
This trial tests a new medicine called JSKN016HC for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it works in the body.
Hear when a new Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.